FDA Accepted Rani Therapeutics Into Technology Program

The agency’s Emerging Technology Program will now provide regulatory feedback on the company’s oral pill platform.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a single pharmaceutical capsule on a metallic surface, symbolizing drug delivery innovation. — The FDA has accepted Rani Therapeutics into its Emerging Technology Program to provide regulatory feedback on the company’s oral biologics pill platform. AI Illustration. Upload story photo >

Live Poll

Should the FDA provide early, collaborative support to companies developing novel pharmaceutical delivery technologies?

The FDA has accepted the RaniPill Capsule, a technology designed for the oral delivery of biologics, into its Emerging Technology Program. This move allows the company to engage directly with regulatory teams on the technical development of its delivery system.

Why it matters

The program helps developers address regulatory hurdles for innovative drug delivery methods that fall outside established review precedents. By participating, Rani Therapeutics gains a dedicated feedback loop to refine its approach to complex manufacturing.

The RaniPill platform enables oral delivery of biologics, a class of drugs typically requiring injection. Participation in the program provides access to the FDA Emerging Technology Team to address technical design questions ahead of broader clinical use.

The players

Rani Therapeutics

A San Jose-based developer focused on creating oral delivery systems for biologic drugs to replace traditional injections.

FDA Emerging Technology Team

A specialized unit within the Food and Drug Administration that evaluates innovative product designs and manufacturing processes.

The details

The RaniPill platform is designed to overcome the challenge of delivering biologics—large, complex proteins that are often destroyed by stomach acid—through an oral route. Rani Therapeutics, headquartered in San Jose, plans to utilize the FDA’s guidance to help automate its manufacturing process. The Emerging Technology Program facilitates this by offering pre-submission meetings and site visits to evaluate how the underlying technology functions before it is applied to specific pharmaceutical products.

October 5, 2026: Rani Therapeutics announced its acceptance into the Emerging Technology Program.

The Tech Race

This move places the RaniPill platform alongside other advanced manufacturing and delivery methods being vetted by the FDA. The company is now positioned to align its internal development roadmap with federal oversight standards through the FDA Emerging Technology Program.

This development does not yet affect patients, as the FDA engagement focuses on technical and manufacturing standards rather than immediate product availability. The primary change is an accelerated feedback loop for the manufacturer that could eventually inform the design of future oral-delivered treatments.

The takeaway

The FDA’s acceptance provides a clear, high-level verification of the company’s technical approach to oral biologics. Stakeholders should watch for future updates on manufacturing automation milestones and potential pre-submission meeting outcomes.